Over the last 2 decades, advances in the diagnosis and management of pituitary diseases have made it possible to attain an endocrine “cure” in a large proportion of patients. In other words, tumors can be excised or controlled with drugs, mass effects of the lesion on surrounding structures can be solved, and pituitary deficiencies can be substituted with all relevant hormones. While this is considered a satisfactory outcome for health care providers, patients often suffer from an aftermath of prior endocrine dysfunction exposure, with irreversible effects, both physically and psychologically, which have a great impact on their everyday life. Diagnostic delay, often of several years, adds a negative impact on health perception. This affects their social, professional, and family domains and determines their future life. Understanding that this may occur is important, and health care providers should offer information to prepare the patient for this difficult journey, especially in the case of acromegaly, Cushing disease, or hypopituitarism. In order to maintain a good quality of life (QoL) in the long-term, patients need to adapt to this new situation, something that may be difficult, since they often cannot continue with all the activities and rhythm they used to do. Depression is often the consequence of maladaptation to the new situation, leading to impaired QoL.

1.
Webb
SM
,
Crespo
I
,
Santos
A
,
Resmini
E
,
Aulinas
A
,
Valassi
E
.
MANAGEMENT OF ENDOCRINE DISEASE: quality of life tools for the management of pituitary disease
.
Eur J Endocrinol
.
2017
Jul
;
177
(
1
):
R13
26
.
[PubMed]
0804-4643
2.
Romijn
JA
.
The chronic syndromes after previous treatment of pituitary tumours
.
Nat Rev Endocrinol
.
2016
Sep
;
12
(
9
):
547
56
.
[PubMed]
1759-5029
3.
Andela
CD
,
Scharloo
M
,
Pereira
AM
,
Kaptein
AA
,
Biermasz
NR
.
Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies
.
Pituitary
.
2015
Oct
;
18
(
5
):
752
76
.
[PubMed]
1386-341X
4.
Koltowska-Häggström
M
,
Mattsson
AF
,
Monson
JP
,
Kind
P
,
Badia
X
,
Casanueva
FF
, et al.
Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?
Eur J Endocrinol
.
2006
Jul
;
155
(
1
):
109
19
.
[PubMed]
0804-4643
5.
Mo
D
,
Blum
WF
,
Rosilio
M
,
Webb
SM
,
Qi
R
,
Strasburger
CJ
.
Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study
.
J Clin Endocrinol Metab
.
2014
Dec
;
99
(
12
):
4581
8
.
[PubMed]
0021-972X
6.
Koltowska-Häggström
M
,
Mattsson
AF
,
Shalet
SM
.
Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations
.
Eur J Endocrinol
.
2009
Nov
;
161
Suppl 1
:
S51
64
.
[PubMed]
0804-4643
7.
Webb
SM
,
Badia
X
.
Quality of life in acromegaly
.
Neuroendocrinology
.
2016
;
103
(
1
):
106
11
.
[PubMed]
0028-3835
8.
Tiemensma
J
,
Kaptein
AA
,
Pereira
AM
,
Smit
JW
,
Romijn
JA
,
Biermasz
NR
.
Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly
.
J Clin Endocrinol Metab
.
2011
Nov
;
96
(
11
):
3550
8
.
[PubMed]
0021-972X
9.
Sievers
C
,
Ising
M
,
Pfister
H
,
Dimopoulou
C
,
Schneider
HJ
,
Roemmler
J
, et al.
Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls
.
Eur J Endocrinol
.
2009
Mar
;
160
(
3
):
367
73
.
[PubMed]
0804-4643
10.
Santos
A
,
Resmini
E
,
Gómez-Ansón
B
,
Crespo
I
,
Granell
E
,
Valassi
E
, et al.
Cardiovascular risk and white matter lesions after endocrine control of Cushing’s syndrome
.
Eur J Endocrinol
.
2015
Dec
;
173
(
6
):
765
75
.
[PubMed]
0804-4643
11.
Lobatto
DJ
,
Steffens
AN
,
Zamanipoor Najafabadi
AH
,
Andela
CD
,
Pereira
AM
,
van den Hout
WB
, et al.
Work disability and its determinants in patients with pituitary tumor-related disease
.
Pituitary
.
2018
Dec
;
21
(
6
):
593
604
.
[PubMed]
1386-341X
12.
Wexler
T
,
Gunnell
L
,
Omer
Z
,
Kuhlthau
K
,
Beauregard
C
,
Graham
G
, et al.
Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly
.
J Clin Endocrinol Metab
.
2009
Jul
;
94
(
7
):
2471
7
.
[PubMed]
0021-972X
13.
Badia
X
,
Forsythe
A
,
Nelson
LM
,
Coles
TM
,
McLeod
LD
,
Webb
SM
.
Improvements in health-related quality of life in acromegaly with pasireotide LAR and octreotide LAR: results from a large, randomized, double-blind phase III trial. In Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Berlin, Germany, 3–7 November 2012
.
Value Health
.
2012
;
15
:
A505
. 1098-3015
14.
Neggers
SJ
,
van Aken
MO
,
de Herder
WW
,
Feelders
RA
,
Janssen
JA
,
Badia
X
, et al.
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
.
J Clin Endocrinol Metab
.
2008
Oct
;
93
(
10
):
3853
9
.
[PubMed]
0021-972X
15.
Sibeoni
J
,
Manolios
E
,
Verneuil
L
,
Chanson
P
,
Revah-Levy
A
.
Patients’ perspectives on acromegaly diagnostic delay: a qualitative study
.
Eur J Endocrinol
.
2019
Jun
;
180
(
6
):
339
52
.
[PubMed]
0804-4643
16.
van Aken
MO
,
Pereira
AM
,
Biermasz
NR
,
van Thiel
SW
,
Hoftijzer
HC
,
Smit
JW
, et al.
Quality of life in patients after long-term biochemical cure of Cushing’s disease
.
J Clin Endocrinol Metab
.
2005
Jun
;
90
(
6
):
3279
86
.
[PubMed]
0021-972X
17.
Valassi
E
,
Feelders
R
,
Maiter
D
,
Chanson
P
,
Yaneva
M
,
Reincke
M
, et al.;
ERCUSYN Study Group
.
Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing’s disease than patients with cortisol producing adenoma. Data from the ERCUSYN
.
Clin Endocrinol (Oxf)
.
2018
Jun
;
88
(
6
):
787
98
.
[PubMed]
0300-0664
18.
van der Klaauw
AA
,
Kars
M
,
Biermasz
NR
,
Roelfsema
F
,
Dekkers
OM
,
Corssmit
EP
, et al.
Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas
.
Clin Endocrinol (Oxf)
.
2008
Nov
;
69
(
5
):
775
84
.
[PubMed]
0300-0664
19.
Andela
CD
,
Lobatto
DJ
,
Pereira
AM
,
van Furth
WR
,
Biermasz
NR
.
How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review
.
Pituitary
.
2018
Apr
;
21
(
2
):
208
16
.
[PubMed]
1386-341X
20.
Liu
S
,
Adelman
DT
,
Xu
Y
,
Sisco
J
,
Begelman
SM
,
Webb
SM
, et al.
Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly
.
J Investig Med
.
2018
Mar
;
66
(
3
):
653
60
.
[PubMed]
1081-5589
21.
Martínez-Momblán
MA
,
Gómez
C
,
Santos
A
,
Porta
N
,
Esteve
J
,
Úbeda
I
, et al.
A specific nursing educational program in patients with Cushing’s syndrome
.
Endocrine
.
2016
Jul
;
53
(
1
):
199
209
.
[PubMed]
1355-008X
22.
Santos
A
,
Webb
SM
. Coping with Cushing’s Disease: the Patients’ Perspectives. In:
Laws
ER
, editor
.
Cushing’s Disease. An often misdiagnosed and not so rare disorder
.
Amsterdam
:
Elsevier
;
2017
. pp.
169
85
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.